First Patient Treated With Inari Medical's FDA-Cleared ClotTriever


April 10, 2017—Inari Medical Inc. announced the treatment of the first patient with its ClotTriever thrombectomy system, which received 510(k) marketing clearance from the US Food and Drug Administration on February 16 for the nonsurgical removal of thrombus from the peripheral vasculature.

According to Inari Medical, the ClotTriever system is designed to remove large clot volume from large veins via access sites as small as 6 mm. The ClotTriever does not require use of thrombolytic drugs, which carry significant risk of bleeding and are contraindicated in many patients.

Mark Meissner, MD, commented in the company's announcement, “We are pleased to be the first site to perform a procedure using the ClotTriever system. The ClotTriever removed clot in the iliac vein efficiently, and without the need for thrombolytic drugs.” Dr. Meissner is Professor of Vascular Surgery at the University of Washington Medical Center in Seattle, Washington. Sandeep Vaidya, MD, Associate Professor of Interventional Radiology, added, “The ClotTriever is a promising new advancement in the treatment of thrombus in large veins.”


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.